Auto/allo-immune defense receptors for the selective targeting of activated pathogenic t cells and nk cells

Abstract

Embodiments of the disclosure concern engineered auto / allo-immune defense receptor (ADR)-expressing T cells that selectively target activated T cells, including pathogenic T cells, to incapacitate them. The chimeric receptors comprise moieties for targeting 4-1BB, OX40, and CD40L, for example, whose expression is indicative of activated T cells. In particular embodiments, there are methods of preventing or treating conditions associated with activated T cells using adoptive T-cell transfer of cells encoding the ADRs.

Description

[0001]This application is a continuation of U.S. Non-Provisional application Ser. No. 17 / 049,561 filed Oct. 21, 2020 which is a national phase application under 35 U.S.C. § 371 that claims priority to International Application No. PCT / US2019 / 029163 filed Apr. 25, 2019, which claims priority to U.S. Provisional Patent Application 62 / 662,817, filed Apr. 26, 2018, all of which are incorporated by reference herein in their entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]This invention was made with government support under P50 CA126752 awarded by National Institutes of Health and the National Cancer Institute. The government has certain rights in the invention.INCORPORATION OF SEQUENCE LISTING[0003]The instant application contains a Sequence Listing, named “Seq_Listing.txt” (18,804 bytes), created Feb. 26, 2021, which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety.TECHNICAL FIELD[0004]Embodiments of...

AI Technical Summary

Benefits of technology

[0010]In particular embodiments, cells encompassed by the disclosure have been modified or can be modified to allow them to survive in a recipient, including an allogeneic recipient. In specific cases, cells for adoptive cell therapy (including T cells, NKT cells, and so forth) are suitable for being utilized “Off-the-shelf”, which herein refers to cells kept in a repository, or bank, that may be provided (with or without further modification) to an individual in need thereof for a specific purpose. The individual in many cases is not the individual from which the cells were originally derived. The cells utilized in such a manner may be pre-manufactured to express an ADR, although in some cases the cells are obtained from a bank and afterwards are modified to express an ADR. The banked cells may or may not also express a CAR or recombinant TCR, or the cells obtained from the bank may afterwards be modified to express a CAR or recombinant TCR. Such practices allow for ease of use of third party-derived therapeutic cells without immune rejection by a host and without having to manufacture a patient-specific produce every time one is needed.

[0015]In one embodiment there is a method of avoiding rejection of allogeneic cells, tissue, or organs in an individual, comprising the step of delivering to the individual an effective amount of allogeneic immune cells expressing an engineered chimeric receptor that comprises an extracellular domain that targets compounds that are selectively present on activated T cells and that comprises CD3 zeta, wherein the delivering step results in the following in the individual: (1) inhibition of endogenous alloreactive T cells in the individual; and / or (2) suppression of NK cell activation in the individual. In specific embodiments, the allogeneic cells are the allogeneic immune cells expressing the chimeric receptor. The allogeneic cells may express a chimeric antigen receptor and / or an engineered T cell receptor. The allogeneic immune cells may be delivered to the individual before, during, and / or after tissue and / or organ transplantation in the individual. In specific cases, the activated T cells are pathogenic T cells.

[0018]In one embodiment, there is a method of avoiding NK cell-mediated host rejection of allogeneic T cells, tissues, or organs in an individual, comprising the step of providing to the individual an effective amount of immune cells expressing an engineered chimeric receptor that comprises an extracellular domain that targets compounds that are selectively present on activated T cells and that also comprises a signaling domain promoting T-cell activation. The immune cells expressing the engineered chimeric receptor are the allogeneic T cells, in certain cases. The immune cells may express a chimeric antigen receptor and / or an engineered T cell receptor. The amount of immune cells expressing the engineered chimeric receptor that are provided to the individual may be in a range of 102-1012 per m2. The cells expressing the chimeric receptor may be provided to the individual systemically or locally. The immune cells may be T cells. The immune cells may be delivered to the individual once or more than once.

Problems solved by technology

Although some steps may be taken to reduce the reactivity of allogeneic cells in the recipient individual, such cells would still be targeted by the immune system of the recipient (primarily T- and NK-cells), which would recognize them as foreign leading to rejection and limiting therapeutic benefit.

Images